Multidimensional factors associated with cognitive impairment: the roles of depression, sarcopenia, frailty, and chronic diseases in community-dwelling older women Authors: Namsu Kim, Sam-Jun Lee, Jinseok Lee Published: 2026 ABSTRACT AbstractAs population aging accelerates globally, cognitive impairment has emerged as a major public health concern, particularly among older women. This study aimed to examine the independent and combined associations of depression, sarcopenia, frailty, and chronic diseases with cognitive impairment in community-dwelling older women in South Korea. A total of 1,065 women aged ≥65 years were recruited from 13 cities. Cognitive function was assessed using the Mini-Mental State Examination for Dementia Screening. Depression, sarcopenia, and frailty were evaluated using the Geriatric Depression Scale-Short Form, Strength, Assistance in walking, Rising from a chair, Climbing stairs and Falls questionnaire, and Fried frailty criteria. Information on physician-diagnosed chronic diseases (diabetes, arthritis, and hypertension) was also collected. Continuous variables were analyzed using independent t-tests, and categorical variables were analyzed using chi-square tests. Multivariable logistic regression analyses were performed to identify factors associated with cognitive impairment, adjusting for age group, depression, diabetes, hypertension, arthritis, sarcopenia, and frailty. Participants with cognitive impairment exhibited significantly higher levels of depression, sarcopenia, frailty, and a greater prevalence of chronic diseases compared to those with normal cognition. In multivariable analyses, depression, diabetes, arthritis, sarcopenia, and frailty remained significantly associated with cognitive impairment. These findings indicate that cognitive impairment in older women is associated with a complex interplay of psychological, physical, and metabolic factors. Addressing modifiable conditions, particularly depression, sarcopenia, and frailty, may be important for reducing the burden of cognitive impairment.Keywords: Cognitive function, Sarcopenia, Frailty, Depression, Chronic disease INTRODUCTION The global population is aging at an unprecedented pace, driven by advances in medical care and improvements in social welfare systems (Jakovljevic et al., 2020). Among Organization for Economic Co-operation and Development countries, South Korea is undergoing the most rapid demographic shift toward an aging society, largely due to persistently low fertility rates. As the proportion of older adults continues to grow, maintaining cognitive health has become an increasingly important public health priority. Cognitive decline not only diminishes quality of life and independence in older adults but also places a substantial burden on healthcare systems and caregivers. Aging is associated with progressive physiological changes, including declines in skeletal muscle mass, muscle strength, and physical performance, along with an increased prevalence of chronic diseases (Ponti et al., 2020). Together, these changes are linked to functional limitations and a higher likelihood of disability. Chronic conditions such as diabetes, arthritis, and hypertension have been widely reported to be associated with cognitive decline. These conditions are also related to various biological processes, including reduced cerebral perfusion, chronic inflammation, metabolic dysregulation, and neurodegeneration (Livingston et al., 2020; Patel and Edison, 2024). In South Korea, the number of individuals living with dementia has risen sharply, from 176,746 cases in 2008 to nearly 960,000 in 2023, highlighting the urgent need to identify modifiable factors associated with cognitive impairment and to develop effective prevention strategies (Choi et al., 2021). Sarcopenia, defined as the age-related loss of skeletal muscle mass and strength, is a major geriatric condition with growing clinical importance (Cruz-Jentoft et al., 2019). Increasing evidence suggests that sarcopenia is associated with cognitive impairment. One possible explanation is that skeletal muscle functions as an endocrine organ, releasing myokines such as brain-derived neurotrophic factor (BDNF), irisin, and insulin-like growth factor-1 (IGF-1), which are involved in neurogenesis and synaptic plasticity (Pedersen, 2019). Declines in muscle mass and strength may be related to reduced neuroprotective effects and poorer cognitive function. Frailty, characterized by decreased physiological reserve and increased vulnerability to stressors, is another important condition associated with adverse health outcomes, including cognitive decline (Fried et al., 2001). The co-occurrence of frailty and cognitive impairment, often referred to as cognitive frailty, represents a particularly high-risk condition in older adults and has been linked to increased risks of disability, institutionalization, and mortality (Fabricio et al., 2020). In addition to physical conditions, depression is also associated with cognitive impairment and may be related to neuroendocrine dysregulation, inflammatory responses, and structural brain changes, particularly in the hippocampus. Likewise, chronic metabolic diseases are associated with neurodegenerative processes through mechanisms such as oxidative stress, vascular dysfunction, and persistent inflammation (Serhal et al., 2020; Sinclair and Abdelhafiz, 2020). Although a growing body of research has identified individual risk factors for cognitive decline, relatively few studies have examined the combined effects of these multidimensional factors within a single framework. This gap is especially evident among community-dwelling older women, who are at greater risk for both sarcopenia and cognitive impairment in rapidly aging societies such as South Korea. Therefore, this study aimed to examine the independent and combined associations of sarcopenia, frailty, depression, and chronic diseases with cognitive impairment among community-dwelling older women in South Korea. MATERIALS AND METHODS Participants This cross-sectional study included 1,065 community-dwelling older women aged 65 years or older who voluntarily participated in the “2023 Anti-Aging Customized Service Project,” a government-funded initiative in South Korea. Participants were recruited from 13 cities and counties in G Province. Data were collected through face-to-face surveys conducted at 80 community centers and senior welfare facilities between May and November 2023. Prior to participation, all individuals received a detailed explanation of the study objectives and procedures and provided written informed consent. Study design A cross-sectional, descriptive study design was adopted to investigate sociodemographic, clinical, and functional factors associated with cognitive status among older adults. Surveys were administered in written form between May and November 2023. Prior to data collection, all research personnel completed a four week intensive training program covering survey administration procedures and content to ensure data reliability. Sociodemographic variables included height, weight, age, and residential area. In addition, information regarding the presence of chronic conditions such as diabetes, arthritis, and hypertension was collected. Participants also completed structured questionnaires assessing cognitive function, depression, sarcopenia, and frailty. Trained interviewers directly measured participants’ height and weight and conducted structured face-to-face interviews to obtain comprehensive survey data. Body composition Participants’ height and weight were measured using an automated height–weight scale (Model SD-102, Biospace Co., Korea). Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2). Before anthropometric assessment, participants were instructed to maintain adequate hydration, refrain from alcohol consumption and vigorous physical activity for at least 24 hr, and wear light cotton clothing without metallic accessories. To ensure measurement accuracy and participant safety, all assessments were conducted after participants had rested in a seated position. For individuals with limited balance or mobility, trained research staff provided assistance throughout the procedure. Questionnaire assessment Cognitive function Cognitive function was assessed using the Korean version of the Mini-Mental State Examination for Dementia Screening (MMSE-DS), developed as part of the National Dementia Screening Program. The MMSE-DS consists of 19 items assessing multiple cognitive domains, including orientation, memory, attention, language, executive function, and visuospatial ability (Han et al., 2010). The use of culturally adapted and validated neuropsychological instruments is essential to ensure accurate assessment of cognitive function in diverse populations (Gkintoni and Nikolaou, 2024). Total scores range from 0 to 30, with higher scores indicating better cognitive performance. Based on established guidelines, participants were categorized as normal cognition (≥24), mild cognitive impairment (20–23), or suspected dementia (≤19). For the primary analysis, participants were classified into two groups: normal cognition and cognitive impairment (Mitchell, 2009). Mild cognitive impairment and suspected dementia were combined into a single cognitive impairment group to enhance statistical power and to allow a clear distinction between normal cognition and overall cognitive decline, which is consistent with previous studies using screening-based classifications. Depression Depressive symptoms were assessed using the Korean version of the Geriatric Depression Scale-Short Form (GDS-SF). The GDS-SF includes 15 dichotomous (yes/no) items evaluating mood, motivation, and life satisfaction. Total scores range from 0 to 15, with higher scores indicating greater depressive severity. Participants were categorized as normal (≤5), mild to moderate depression (6–9), or severe depression (≥10), based on validated cutoff values. Sarcopenia and frailty Sarcopenia was assessed using the Strength, Assistance in walking, Rising from a chair, Climbing stairs and Falls (SARC-F) questionnaire (Malmstrom et al., 2016). The SARC-F is a brief self-reported screening tool designed to identify individuals at risk of sarcopenia. Scores range from 0 to 10, with higher scores indicating greater functional impairment, and a total score of ≥4 representing a risk of sarcopenia. Frailty was evaluated using the criteria proposed (Fried et al., 2001), which were translated and adapted into Korean (Hwang et al., 2010). This tool assesses five components: unintentional weight loss, exhaustion, low physical activity, slowness, and weakness. Participants who met three or more criteria were classified as frailty. Chronic disease - diabetes, arthritis, hypertension The presence of chronic diseases, including diabetes, arthritis, and hypertension, was determined based on physician diagnosis within the past three years or recent national health examination records, along with documented use of prescribed medications. Statistical analysis Continuous variables are presented as means±standard deviation, and categorical variables are expressed as frequencies and percentages. Differences between the normal cognition and cognitive impairment groups were analyzed using independent t-tests for continuous variables and chi-square tests for categorical variables. Age was categorized into three groups (65–75, 76–86, and >86 years) and included as a covariate in the regression models. This categorization reflects the nonlinear relationship between aging and cognitive decline, as previous studies have shown that aging is a major determinant of cognitive impairment and that the burden of cognitive decline increases substantially in older age groups, particularly after the mid-70s and in the oldest-old population (≥80 years) (Albuloshi et al., 2025). These variables were selected based on their statistical significance in the univariate analysis and their clinical relevance. All covariates were entered simultaneously into the multivariable logistic regression model using the enter method. The normal cognition group was used as the reference category for the dependent variable, and the absence of each condition (e.g., no depression, no chronic disease, no sarcopenia, and nonfrailty) was used as the reference for independent variables. Multicollinearity was assessed using variance inflation factors, and all values were <2.0. Model goodness-of-fit was evaluated using the Hosmer–Lemeshow test and the area under the receiver operating characteristic curve. Odds ratio (OR) and 95% confidence interval (CI) were calculated. All analyses were performed using SAS 9.4 (SAS Institute Inc., USA), and a two-tailed P-value <0.05 was considered statistically significant. RESULTS This study examined differences in sociodemographic characteristics, depression, sarcopenia, frailty, and chronic diseases according to cognitive function status among community-dwelling older women in South Korea. Table 1 presents the demographic characteristics of the participants according to cognitive function status. No significant differences were observed between the normal cognition and cognitive impairment groups in age, height, weight, or BMI (P>0.05). Table 2 shows the comparison of depressive symptoms between the two groups. Depression scores were significantly higher in the cognitive impairment group than in the normal cognition group (P<0.05). Table 3 compares sarcopenia and frailty scores according to cognitive function status. Both sarcopenia and frailty scores were higher in the cognitive impairment group than in the normal cognition group (P<0.01). Table 4 presents the prevalence of chronic diseases according to cognitive function status. Diabetes and arthritis were significantly more prevalent in the cognitive impairment group than in the normal cognition group (P<0.001 for both). Conversely, hypertension was significantly more prevalent in the normal cognition group (P=0.027). In contrast, hypertension showed a significantly higher prevalence in the normal cognition group compared with the cognitive impairment group (P<0.05). Table 5 summarizes the results of the univariate and multivariate logistic regression analyses examining factors associated with cognitive impairment. In the univariate analysis, individuals aged ≥86 years were significantly associated with cognitive impairment (OR, 1.492; P<0.05), whereas depression (OR, 15.420; P<0.01), diabetes (OR, 4.967; P<0.01), hypertension (OR, 2.573; P<0.01), arthritis (OR, 3.158; P<0.01), sarcopenia (OR, 7.386; P<0.01), and frailty (OR, 8.399; P<0.01) were also significantly associated with cognitive impairment. In the multivariate logistic regression analysis, depression (OR, 11.105; 95% CI, 6.972–16.064; P<0.01), diabetes (OR, 3.011; 95% CI, 2.952–4.956; P<0.01), arthritis (OR, 1.745; 95% CI, 1.232–2.502; P<0.01), sarcopenia (OR, 2.115; 95% CI, 1.480–3.161; P<0.01), and frailty (OR, 3.961; 95% CI, 2.514–6.097; P<0.01) remained significantly associated with cognitive impairment after adjustment for covariates, whereas hypertension was not significant in the adjusted model (P>0.05). Table 1Demographic and anthropometric characteristics according to cognitive statusVariableNC (n=754)CI (n=311) t P-valueTotal754/1.065 (70.8)311/1.065 (29.2) Age (yr)78.5±7.179.0±7.30.2960.707 65–75238/325 (31.6)87/325 (28.0) 76–86338/489 (44.8)151/489 (48.6) >86178/251 (23.6)73/251 (23.5) Height (cm)153.0±4.9150.9±6.90.7310.465 Weight (kg)57.5±10.557.3±9.6−0.9410.347 BMI (kg/m2)24.1±3.724.4±3.4−1.5170.130Values are presented as number (%) or mean±standard deviation.NC, normal cognitive group; CI, cognitive impairment group; BMI, body mass index. Demographic and anthropometric characteristics according to cognitive status Values are presented as number (%) or mean±standard deviation. NC, normal cognitive group; CI, cognitive impairment group; BMI, body mass index. Table 2Differences in depressive symptoms according to cognitive statusVariableNC (n=754)CI (n=311) t P-valueDepressive score1.1±2.08.5±3.6−2.2700.023Values are presented as mean±standard deviation.NC, normal cognitive group; CI, cognitive impairment group. Differences in depressive symptoms according to cognitive status Values are presented as mean±standard deviation. NC, normal cognitive group; CI, cognitive impairment group. Table 3Differences in sarcopenia and frailty according to cognitive statusVariableNC (n=754)CI (n=311) t P-valueSarcopenia score2.5±2.46.3±2.5−15.4280.001Frailty score3.1±3.24.1±3.2−13.6100.001Values are presented as mean±standard deviation.NC, normal cognitive group; CI, cognitive impairment group. Differences in sarcopenia and frailty according to cognitive status Values are presented as mean±standard deviation. NC, normal cognitive group; CI, cognitive impairment group. Table 4Differences in chronic diseases according to cognitive statusVariableNC (n=754)CI (n=311)χ2P-valueDiabetes271 (35.9)132 (42.4)50.665<0.001Arthritis290 (38.5)126 (40.5)34.215<0.001Hypertension193 (25.6)53 (17.0)4.8940.027Values are presented as number (%).NC, normal cognitive group; CI, cognitive impairment group. Differences in chronic diseases according to cognitive status Values are presented as number (%). NC, normal cognitive group; CI, cognitive impairment group. Table 5Univariate and multivariable logistic regression analyses of factors associated with cognitive impairmentVariableUnivariate analysisMultiple analysis OR95% CIP-valueOR95% CIP-valueAge (yr) 65–75Ref.Ref. 76–861.2340.948–1.6100.1181.0940.855–1.4380.622 >861.4921.038–2.1360.0291.3861.014–2.0120.173 Depression NormalRef.Ref. Diagnosed15.42011.009–21.9280.00111.1056.972–16.0640.001 Diabetes NormalRef.Ref. Diagnosed4.9673.827–6.4650.0013.0112.952–4.9560.001 Hypertension NormalRef.Ref. Diagnosed2.5732.020–3.2850.0011.3130.951–1.8090.097 Arthritis NormalRef.Ref. Diagnosed3.1582.473–4.0430.0011.7451.232–2.5020.001 Sarcopenia NormalRef.Ref. Diagnosed7.3865.683–9.6410.0012.1151.480–3.1610.001 Frailty NormalRef.Ref. Diagnosed8.3996.141–11.6970.0013.9612.514–6.0970.001OR, odds ratio; CI, confidence interval. Univariate and multivariable logistic regression analyses of factors associated with cognitive impairment OR, odds ratio; CI, confidence interval. DISCUSSION The present study examined multidimensional factors associated with cognitive impairment among community-dwelling older women in South Korea, with a particular focus on sarcopenia, frailty, depression, and chronic diseases. After adjusting for relevant covariates, depression, diabetes, arthritis, sarcopenia, and frailty remained significantly associated with cognitive impairment. Importantly, this study extends previous research by simultaneously examining psychological, physical, and metabolic factors within a single analytical framework, thereby providing a more integrated understanding of cognitive impairment in older women. Among the identified factors, depression demonstrated the strongest association with cognitive impairment. This finding is consistent with previous research suggesting that depressive symptoms are associated with neurocognitive decline through multiple biological pathways, including dysregulation of the hypothalamic-pituitary-adrenal axis, prolonged glucocorticoid exposure, hippocampal atrophy, and increased systemic inflammation (Frodl et al., 2012; Jo et al., 2020). In addition, depression in later life has been associated with adverse functional outcomes, including increased fear of falling and a higher risk of falls, reflecting broader impairments in physical and psychological resilience (Gambaro et al., 2022). From a clinical perspective, this highlights the importance of early identification and management of depressive symptoms as a potentially modifiable factor associated with cognitive impairment (Livingston et al., 2020). Chronic diseases, particularly diabetes and arthritis, were also significantly associated with cognitive impairment. This finding is consistent with previous research indicating that arthritis is independently associated with an increased risk of cognitive impairment in older adults (Baker et al., 2017). Furthermore, chronic metabolic and inflammatory conditions are associated with impaired brain health through mechanisms such as microvascular dysfunction, insulin resistance, oxidative stress, and persistent low-grade inflammation (Serhal et al., 2020; Sinclair and Abdelhafiz, 2020). These pathophysiological processes may be related to neuronal dysfunction and cognitive decline. Sarcopenia emerged as another important factor associated with cognitive impairment, which is consistent with previous systematic review and meta-analysis findings demonstrating an association between sarcopenia and cognitive decline (Chang et al., 2016). Recent studies have suggested that muscle strength, rather than muscle mass alone, may be more strongly associated with cognitive outcomes. This aligns with the concept of muscle-brain crosstalk, whereby skeletal muscle functions as an endocrine organ that releases myokines, including BDNF and irisin, which are involved in neurogenesis and synaptic plasticity (Pedersen, 2019). Consequently, declines in muscle function may be associated with reduced neuroprotective effects and poorer cognitive function. Frailty also showed a strong association with cognitive impairment, consistent with previous systematic review and meta-analysis findings identifying frailty as a factor associated with cognitive disorders (Borges et al., 2019). This supports earlier findings that frailty and cognitive decline share common biological mechanisms, including mitochondrial dysfunction, chronic inflammation, and reduced physiological reserve (Fabricio et al., 2020). The co-occurrence of frailty and cognitive impairment, often referred to as cognitive frailty, may represent a particularly vulnerable clinical state associated with accelerated functional decline and increased risk of adverse outcomes. Taken together, these findings suggest that cognitive impairment in older women is associated with a complex interplay of multiple risk domains. Importantly, many of these factors are potentially modifiable. From a clinical and public health perspective, integrating assessments of muscle strength, frailty status, depressive symptoms, and chronic disease management into community-based screening programs may facilitate early identification of individuals at higher likelihood of cognitive impairment. In addition, accumulating evidence from randomized controlled trials indicates that resistance training, particularly when combined with cognitive or multicomponent exercise interventions, is associated with improvements in both physical and cognitive outcomes in older adults (Montero-Odasso et al., 2023). Given the relatively high prevalence of sarcopenia and frailty among older women, such targeted interventions may be especially beneficial in this population. This study has several strengths. First, it included a relatively large sample of community-dwelling older women recruited from multiple regions, enhancing the generalizability of the findings. Second, multiple interrelated factors were examined simultaneously within a single analytical framework, allowing for a more comprehensive understanding of multidimensional associations with cognitive impairment. However, several limitations should be considered. The cross-sectional design precludes causal inferences regarding the observed associations. In addition, cognitive function, depression, sarcopenia, and frailty were assessed using screening tools (MMSE-DS, GDS-SF, SARC-F, and Fried criteria) rather than clinical diagnostic or objective performance-based measures, which may introduce measurement bias and potential misclassification. In particular, the SARC-F questionnaire reflects functional limitations and the risk of sarcopenia rather than providing a definitive diagnosis based on objective measures such as muscle mass or muscle strength. Furthermore, several potentially important confounding variables, including educational level, physical activity, nutritional status, medication use, and inflammatory biomarkers, were not included in the regression model. These factors may substantially influence cognitive outcomes and could have affected the observed associations. Therefore, the findings of this study should be interpreted with caution. Finally, the findings may not be generalizable to institutionalized populations or to the elderly. Future studies should employ longitudinal designs to clarify the temporal and causal relationships between these risk factors and cognitive decline. Incorporating objective assessments of muscle function, comprehensive neuropsychological testing, neuroimaging, and biological markers such as BDNF, IGF-1, and inflammatory cytokines would provide deeper insight into the underlying mechanisms. In addition, well-designed intervention studies are needed to determine whether improving muscle strength and reducing frailty is associated with better cognitive outcomes. In conclusion, the present study demonstrates that depression, sarcopenia, frailty, and chronic disease burden are significantly associated with cognitive impairment among community-dwelling older women. These findings highlight the importance of integrated, multidimensional approaches for addressing cognitive health in rapidly aging populations. Footnotes CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported. ACKNOWLEDGMENTS This study was conducted with the support G province office. REFERENCES